Sara N. Hanson

626 total citations
12 papers, 344 citations indexed

About

Sara N. Hanson is a scholar working on Infectious Diseases, Neurology and Clinical Psychology. According to data from OpenAlex, Sara N. Hanson has authored 12 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 7 papers in Neurology and 2 papers in Clinical Psychology. Recurrent topics in Sara N. Hanson's work include SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (10 papers) and Long-Term Effects of COVID-19 (7 papers). Sara N. Hanson is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (10 papers) and Long-Term Effects of COVID-19 (7 papers). Sara N. Hanson collaborates with scholars based in United States. Sara N. Hanson's co-authors include Ravindra Ganesh, Raymund R. Razonable, Sidna M. Tulledge‐Scheitel, Dennis M. Bierle, Caroline G. Wilker, Richard Arndt, Leigh L. Speicher, Lori L. Arndt, John C. O’Horo and Jennifer J. Larsen and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and The Journal of Infectious Diseases.

In The Last Decade

Sara N. Hanson

12 papers receiving 340 citations

Peers

Countries citing papers authored by Sara N. Hanson

Since Specialization

Citations

This map shows the geographic impact of Sara N. Hanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara N. Hanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara N. Hanson more than expected).

Fields of papers citing papers by Sara N. Hanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara N. Hanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara N. Hanson. The network helps show where Sara N. Hanson may publish in the future.

Co-authorship network of co-authors of Sara N. Hanson

This figure shows the co-authorship network connecting the top 25 collaborators of Sara N. Hanson. A scholar is included among the top collaborators of Sara N. Hanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara N. Hanson. Sara N. Hanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Postacute Sequelae of SARS-CoV-2 Infection—Lessons Learned From a Coordinated Health System Response 2022 ·SHILAP Revista de lepidopterología ·Ravindra Ganesh, Greg Vanichkachorn, Bala Munipalli, Sara N. Hanson, Abd Moain Abu Dabrh, Ivana T. Croghan, Nancy L. Dawson, Ryan T. Hurt	7
2	Curbing the Delta Surge 2022 ·Mayo Clinic Proceedings ·Raymund R. Razonable, John C. O’Horo, Douglas W. Challener, Lori L. Arndt, Richard Arndt, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer Larsen, Sara N. Hanson, (unknown), Sidna M. Tulledge‐Scheitel, Ravindra Ganesh	5
3	Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch 2022 ·The Journal of Infectious Diseases ·Raymund R. Razonable, John C. O’Horo, Sara N. Hanson, Richard Arndt, Leigh L. Speicher, (unknown), (unknown), (unknown), (unknown), Jennifer J. Larsen, Ravindra Ganesh, Sidna M. Tulledge‐Scheitel	28
4	Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch 2022 ·Open Forum Infectious Diseases ·Raymund R. Razonable, Sidna M. Tulledge‐Scheitel, Sara N. Hanson, Richard Arndt, Leigh L. Speicher, (unknown), Jennifer J. Larsen, Ravindra Ganesh, John C. O’Horo	19
5	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities 2021 ·The Journal of Infectious Diseases ·Dennis M. Bierle, Ravindra Ganesh, Sidna M. Tulledge‐Scheitel, Sara N. Hanson, Lori L. Arndt, Caroline G. Wilker, Raymund R. Razonable	31
6	Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant 2021 ·Mayo Clinic Proceedings ·John C. O’Horo, Douglas W. Challener, Leigh L. Speicher, Wendelyn Bosch, Maria Teresa Seville, Dennis M. Bierle, Ravindra Ganesh, Caroline G. Wilker, Richard Arndt, Lori L. Arndt, Sidna M. Tulledge‐Scheitel, Sara N. Hanson, Raymund R. Razonable	16
7	Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 2021 ·EClinicalMedicine ·Raymund R. Razonable, Colin Pawlowski, John C. O’Horo, Lori L. Arndt, Richard Arndt, Dennis M. Bierle, (unknown), Sara N. Hanson, (unknown), Patrick J. Lenehan, Arjun Puranik, Maria Teresa Seville, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Ravindra Ganesh	97
8	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 2021 ·Journal of Clinical Investigation ·Ravindra Ganesh, Colin Pawlowski, John C. O’Horo, Lori L. Arndt, Richard Arndt, Sarah Bell, Dennis M. Bierle, (unknown), Sara N. Hanson, (unknown), Jennifer J. Larsen, Patrick J. Lenehan, Robert Orenstein, Arjun Puranik, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Raymund R. Razonable	36
9	Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19 2021 ·SSRN Electronic Journal ·Raymund R. Razonable, Colin Pawlowski, John C. O’Horo, Lori L. Arndt, Richard Arndt, Dennis M. Bierle, (unknown), Sara N. Hanson, (unknown), Patrick J. Lenehan, Arjun Puranik, Leigh L. Speicher, Maria Teresa Seville, Sidna M. Tulledge‐Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Ravindra Ganesh	6
10	A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities 2021 ·Journal of the American Geriatrics Society ·Sidna M. Tulledge‐Scheitel, Sarah Bell, Jennifer J. Larsen, Dennis M. Bierle, Paul Y. Takahashi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sara N. Hanson, Raymund R. Razonable, Ravindra Ganesh	19
11	Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19 2021 ·Journal of Primary Care & Community Health ·Dennis M. Bierle, Ravindra Ganesh, Caroline G. Wilker, Sara N. Hanson, (unknown), (unknown), Priya Ramar, Jordan K. Rosedahl, Lindsey M. Philpot, Raymund R. Razonable	29
12	Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019 2021 ·The Journal of Infectious Diseases ·Ravindra Ganesh, Lindsey M. Philpot, Dennis M. Bierle, Ryan J. Anderson, Lori L. Arndt, Richard Arndt, (unknown), (unknown), Sara N. Hanson, (unknown), (unknown), Jennifer J. Larsen, Priya Ramar, Jordan K. Rosedahl, Maria Teresa Seville, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, Caroline G. Wilker, Raymund R. Razonable	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact